Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer

Official title

A Phase II Study Combining Pembrolizumab With Olaparib in Metastatic Pancreatic Adenocarcinoma (PDA) Patients With Mismatch Repair Deficiency or Tumour Mutation Burden > 4 Mutations/Mb

Overview

A phase II study combining pembrolizumab with olaparib in metastatic pancreatic adenocarcinoma patients with high tumour mutation burden

Detailed description

This is a phase II single arm, open label, prospective trial investigating the efficacy of pembrolizumab plus olaparib in metastatic pancreatic adenocarcinoma patients exhibiting high tumour mutation burden (defined as ≥4 mutations/Mb, including tumours with Mismatch Repair Deficient (MMRD) /Microsatellite Instability (MSI) high).

Interventions

• Drug Pembrolizumab
  Pembrolizumab is a highly selective immunoglobulin G4-kappa humanised monoclonal antibody against Programmed cell death protein 1 (PD-1) receptor. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype with the containing a stabilizing Serine 228 to Proline Fc mutation.
• Drug Olaparib
  Olaparib is a potent inhibitor of polyadenosine 5'diphosphoribose polymerase (PARP) developed as a monotherapy as well as for combination with chemotherapy, ionising radiation and other anti-cancer agents including novel agents and immunotherapy.

Primary outcome measures

• Objective Response Rate (ORR) [Time frame: Through study completion, an average of 2 years]

Secondary outcome measures (6)

• Incidence of adverse events (Safety and toxicity) [Time frame: Through study completion, an average of 2 years]
• Duration of Response (DOR) [Time frame: Through study completion, an average of 2 years]
• Progression Free Survival (PSF) [Time frame: through study completion, a maximum of 2 years]
• Overall survival (OS) [Time frame: through study completion, a maximum of 2 year]
• European Organisation for Research and Treatment of Cancer Quality of Life of Cancer Patients questionnaire (EORTC QLQC30) [Time frame: Every 9 weeks during the first 27 weeks and then every 12 weeks until death or maximum of 2 years]
• European Organisation for Research and Treatment of Cancer Pancreatic Cancer Quality of Life Questionnaire (EORTC PAN26) [Time frame: Every 9 weeks during the first 27 weeks and then every 12 weeks until death or maximum of 2 years]

Eligibility criteria

Inclusion criteria

• Aged ≥ 18 years old
• Written informed consent
• Histologically or cytologically confirmed PDA
• Confirmation that the PDA has TMB >4 mutations/Mb, or dMMR gene mutation, or MSI-H by IHC. TMB status and dMMR can be obtained from either tissue, or blood.
• Radiologically confirmed stage 4 mPDA, with measurable disease
• Received no more than 1 prior systemic therapy regimen for unresectable (stage 3 or 4) PDA is allowed
• Measurable disease which has not been irradiated in prior radiotherapy
• Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1
• Life expectancy >12 weeks from the date of screening assessment
• Adequate bone marrow function:

• Absolute neutrophil count (ANC) ≥1.5 x 109 /L
• Haemoglobin (Hb) ≥ 90 g/L
• Platelets ≥100 x 109 /L
• Adequate liver function:

• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤2.5 x upper limit of normal range (ULN), or <5 x ULN in the presence of liver metastases
• Total bilirubin <1.5 x ULN
• Adequate renal function defined as a calculated creatinine clearance by Cockcroft - Gault of ≥50 mL/min

Exclusion criteria

• Patients with resectable or locally advanced PDA
• Other invasive malignancies diagnosed within the last 2 years which have not been treated with curative intent
• Prior immune checkpoint inhibitors or PARP inhibitors. This includes any prior therapy with an anti-PD-1, or anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g, CTLA-4, OX 40, CD137)
• Requirement for non-physiological dose of daily oral steroids, or regular use of any other immunosuppressive agents; prednisolone dose of < 10mg (or equivalent steroid dose) is allowed. Use of inhaled or topical steroids is allowed.
• Significant acute or chronic medical or psychiatric condition, disease or laboratory abnormality, which in the judgment of the investigator would place the patient at undue risk or interfere with the trial. Examples include, but are not limited to:

• A history of chronic obstructive pulmonary disease, interstitial lung disease, sarcoidosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis, cystic fibrosis or bronchiectasis affecting pulmonary function, causing breathlessness at rest
• Uncontrolled ischaemic heart or other cardiovascular event (myocardial infarction, new angina, stroke transient ischaemic attack, or new congestive cardiac failure) within the last 2 months
• Stable but significant cardiovascular disease defined by heart failure (New York Heart Association Functional Classification III or IV) or frequent angina
• Presence of active infection
• Cirrhotic liver disease, known HIV, chronic active or acute hepatitis B, or hepatitis C
• History of severe allergy or hypersensitivity reactions
• Autoimmune disease requiring chronic use of immunosuppressive agents.
• Replacement therapy using physiological doses for adrenal or pituitary insufficiency is allowed.
• Known additional malignancy that is progressing or has required active treatment within the past 3 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ, excluding carcinoma in situ of the bladder, that have undergone potentially curative therapy are not excluded.
• Has known brain metastases and/or carcinomatous meningitis
• Has myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML) or with features suggestive of MDS/AML.
• Women who are pregnant, or plan to become pregnant or are lactating.
• Women of child-bearing potential and male patients who are unwilling to adhere to the contraception requirement from informed consent until the last dose of the trial treatment and for 120 days after the last dose of trial treatment.
• Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the trial medication.
• Concomitant use of known potent CYP3A4 inhibitors and inducers. Restrictions relating to concomitant medications are described in section 10.9. Please consider wash-out periods.
• Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to screening.
• Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients
• Has received prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.
• Has received a live vaccine or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.
• Participant received colony-stimulating factors (e.g., granulocyte colony-stimulating factor \[G-CSF\], granulocyte-macrophage colony-stimulating factor \[GM CSF\] or recombinant erythropoietin) within 28 days prior to the first dose of study intervention.
• Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention.
• Participant has persistent toxicities (>CTCAE Grade 2) caused by previous cancer therapy, excluding alopecia.
• Has had an allogenic tissue/solid organ transplant
• Judgment by the Investigator that the patient should not participate in the trial.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

United Kingdom · 15 centers

• Addenbrooke's Hospital — Cambridge
• Glan Clwyd Hospital — Bodelwyddan
• Velindre Cancer Centre — Cardiff
• University Hospitals Coventry and Warwickshire — Coventry
• Beatson West of Scotland Cancer Centre — Glasgow
• St James' University Hospital — Leeds
• Clatterbridge Cancer Centre — Liverpool
• Guy's and St Thomas' NHS Foundation Trust — London
• … and 7 more centers

Australia · 2 centers

• Monash Health — Melbourne
• Epworth Healthcare — Richmond

Identifiers

NCT: NCT05093231 · PemOla

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗